— Bob Azelby is leaving his position as president and CEO of Elieum Therapeutics and stepping down from its board. General counsel Jim Bucher and Erin Lavelle, chief operating officer… Read More
In a region better known for its tech startups and legions of software engineers, it’s biotech companies that have helped lead a recent IPO boom in the state of Washington,… Read More
An online marketplace that helps to facilitate trade between marijuana sellers and buyers will soon see its own stock traded on the Nasdaq. Another that connects pet owners with walkers,… Read More
Eliem Therapeutics joined the ranks of publicly traded companies from Washington state, pricing 6.4 million shares at $12.50 and raising $80 million. It originally planned to sell 4.5 million shares… Read More
Eliem Therapeutics, a clinical stage biotech company generating therapies for pain, depression and other nervous-system related conditions, has filed to go public via an IPO. The company’s filing with the… Read More
New funding: Eliem Therapeutics, a new Seattle biotech startup led by former Juno Therapeutics exec Bob Azelby, raised $80 million to develop clinically-validated therapies for pain and depression. The pipeline:… Read More